{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T13:46:44Z","timestamp":1786715204702,"version":"build-2736575974"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Pharmacol"],"published-print":{"date-parts":[[2016]]},"DOI":"10.4103\/0253-7613.178839","type":"journal-article","created":{"date-parts":[[2016,3,16]],"date-time":"2016-03-16T23:30:48Z","timestamp":1458171048000},"page":"186","source":"Crossref","is-referenced-by-count":7,"title":["Bedaquiline versus placebo for management of multiple drug-resistant tuberculosis: A systematic review"],"prefix":"10.4103","volume":"48","author":[{"given":"Jaykaran","family":"Charan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tea","family":"Reljic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambuj","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0253-7613.178839-1","first-page":"1009","volume-title":"The growing burden of tuberculosis: Global trends and interactions with the HIV epidemic","author":"Corbett","year":"2003","journal-title":"Arch Intern Med"},{"key":"key-10.4103\/0253-7613.178839-2","first-page":"1255","volume-title":"Confronting the scientific obstacles to global control of tuberculosis","author":"Young","year":"2008","journal-title":"J Clin Invest"},{"key":"key-10.4103\/0253-7613.178839-3","unstructured":"World Health Organization. Global Tuberculosis Report. World Health Organization; 2014. Available from: . [Last accessed on 2015 Jan 02]."},{"key":"key-10.4103\/0253-7613.178839-4","first-page":"1","volume-title":"Bedaquiline:First FDA-approved tuberculosis drug in 40 years","author":"Mahajan","year":"2013","journal-title":"Int J Appl Basic Med Res"},{"key":"key-10.4103\/0253-7613.178839-5","unstructured":"Administration FAD. FDA News Release. FDA; 2012. Available from: . [Last accessed on 2015 Jan 02]."},{"key":"key-10.4103\/0253-7613.178839-6","first-page":"1290","volume-title":"Selectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologue","author":"Haagsma","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.4103\/0253-7613.178839-7","first-page":"5","volume-title":"Comparative efficacy and acceptability of five anti-tubercular drugs in treatment of multidrug resistant tuberculosis: A network meta-analysis","author":"Wang","year":"2015","journal-title":"J Clin Bioinforma"},{"key":"key-10.4103\/0253-7613.178839-8","first-page":"d5928","volume-title":"The Cochrane collaboration's tool for assessing risk of bias in randomised trials","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"key-10.4103\/0253-7613.178839-9","unstructured":"Review Manager (RevMan) [Computer program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014."},{"key":"key-10.4103\/0253-7613.178839-10","first-page":"b2700","volume-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"key-10.4103\/0253-7613.178839-11","first-page":"2397","volume-title":"The diarylquinoline TMC207 for multidrug-resistant tuberculosis","author":"Diacon","year":"2009","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0253-7613.178839-12","first-page":"3271","volume-title":"Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: Long-term outcome, tolerability, and effect on emergence of drug resistance","author":"Diacon","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.4103\/0253-7613.178839-13","first-page":"723","volume-title":"Multidrug-resistant tuberculosis and culture conversion with bedaquiline","author":"Diacon","year":"2014","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0253-7613.178839-14","first-page":"7","volume-title":"The hazards of randomized phase II trials","author":"Lara","year":"2012","journal-title":"Ann Oncol"},{"key":"key-10.4103\/0253-7613.178839-15","first-page":"5296","volume-title":"Analysis of the yield of phase II combination therapy trials in medical oncology","author":"Maitland","year":"2010","journal-title":"Clin Cancer Res"},{"key":"key-10.4103\/0253-7613.178839-16","first-page":"602","volume-title":"Published methodological quality of randomized controlled trials does not reflect the actual quality assessed in protocols","author":"Mhaskar","year":"2012","journal-title":"J Clin Epidemiol"},{"key":"key-10.4103\/0253-7613.178839-17","first-page":"22","volume-title":"Bad reporting does not mean bad methods for randomised trials: Observational study of randomised controlled trials performed by the Radiation Therapy Oncology Group","author":"Soares","year":"2004","journal-title":"BMJ"},{"key":"key-10.4103\/0253-7613.178839-18","first-page":"46","volume-title":"Randomized trials published in some Chinese journals: How many are randomized?","author":"Wu","year":"2009","journal-title":"Trials"}],"container-title":["Indian Journal of Pharmacology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T13:26:13Z","timestamp":1786713973000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/0253-7613.178839"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016]]}},"alternative-id":["178839"],"URL":"https:\/\/doi.org\/10.4103\/0253-7613.178839","relation":{},"ISSN":["0253-7613"],"issn-type":[{"value":"0253-7613","type":"print"}],"subject":[],"published":{"date-parts":[[2016]]}}}